Stock Price Quote

ZILLION PHARMACHEM LTD.

NSE : NABSE : 524476ISIN CODE : INE845F01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE0.000 (0 %)
PREV CLOSE ( ) NA
OPEN PRICE ( ) 0.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )0.00 0.00
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1992
Management Info
- Chairman - Managing Director
Registered Office

Address Iol House, Ambawadi,,
Ahmedabad,
Gujarat-380006

Phone 079- 6462436 6404276

Email --

Website NA

Registrars Details
Zillion Pharmachem Ltd.
Iol House, Ambawadi,,Ahmedabad
Listing : BSE, NSE

NEWS

No News Found

Financials

in Millions
QTR Sep 03 ANNUAL
Net Profit
Gross Profit
Operating Profit
Net Sales

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Alkem Laboratories (BSE)
peergroup  5460.90 (2.86%)
M.Cap ( in Cr)64785.10
Glaxosmithkline Phar (BSE)
peergroup  2474.50 (4.09%)
M.Cap ( in Cr)41843.29
Gland Pharma (BSE)
peergroup  1880.90 (4.76%)
M.Cap ( in Cr)30778.63
Coral Laboratories (BSE)
peergroup  451.20 (20.00%)
M.Cap ( in Cr)143.98
Pfizer (BSE)
peergroup  4567.85 (1.64%)
M.Cap ( in Cr)21034.81

Shareholding Pattern

No Data Found

About

no data found

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.